Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Ani Pharmaceuticals (ANIP) over the last 14 years, with Q3 2025 value amounting to $93.4 million.

  • Ani Pharmaceuticals' Cost of Revenue rose 4806.02% to $93.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $321.3 million, marking a year-over-year increase of 4386.43%. This contributed to the annual value of $250.2 million for FY2024, which is 3784.69% up from last year.
  • Ani Pharmaceuticals' Cost of Revenue amounted to $93.4 million in Q3 2025, which was up 4806.02% from $74.6 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Cost of Revenue ranged from a high of $93.4 million in Q3 2025 and a low of $20.0 million during Q1 2021
  • Moreover, its 5-year median value for Cost of Revenue was $42.3 million (2023), whereas its average is $48.0 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first plummeted by 834.25% in 2021, then skyrocketed by 7148.36% in 2022.
  • Ani Pharmaceuticals' Cost of Revenue (Quarter) stood at $33.9 million in 2021, then grew by 7.16% to $36.3 million in 2022, then soared by 47.06% to $53.4 million in 2023, then soared by 50.28% to $80.3 million in 2024, then grew by 16.33% to $93.4 million in 2025.
  • Its Cost of Revenue stands at $93.4 million for Q3 2025, versus $74.6 million for Q2 2025 and $73.0 million for Q1 2025.